Genmab
GMAB | NASDAQ
$51.57
+$0.20 (+0.39%)
At close: Nov 16, 2026, 4:00 PM ET
$51.75
+$0.18 (+0.35%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Genmab Company Profile
Company profile explainedCompany Profile
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Key Executives
| Name | Position |
|---|---|
| Jan van de Winkel | Co-Founder, President & Chief Executive Officer |
| Anthony Pagano | Executive Vice President & Chief Financial Officer |
| Christopher Cozic | Executive Vice President & Chief People Officer |
| Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer |
| Judith V. Klimovsky | Executive Vice President & Chief Development Officer |
| Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director |
| Martine J. van Vugt | Executive Vice President & Chief Strategy Officer |
| Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director |
| Rayne Waller | Executive Vice President & Chief Technical Operations Officer |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 6-K | Filing |
| Oct 23, 2026 | 6-K | Filing |
| Oct 13, 2026 | 6-K | Filing |
| Oct 07, 2026 | 6-K | Filing |
| Oct 05, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 05, 2026 | 6-K | Filing |
| Oct 02, 2026 | 6-K | Filing |
| Sep 29, 2026 | 6-K | Filing |
| Sep 24, 2026 | 6-K | Filing |
| Sep 09, 2026 | 6-K | Filing |
Genmab
| Country | Denmark |
| IPO Date | Jun 1, 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,119 |
| CEO | Jan van de Winkel |
Contact Details
Carl Jacobsens Vej 30 Copenhagen,
CD 2500 Denmark
Stock Details
| Ticker Symbol | GMAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434265 |
| CUSIP Number | 372303206 |
| ISIN Number | US3723032062 |
| SIC Code | 2834 |
Recent News
- 5 days ago / fool.comDrug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
- 5 days ago / globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- 6 days ago / globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant Exercise
- 11 days ago / seekingalpha.comGenmab A/S (GMAB) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comWhat Genmab A/S (GMAB) Said on Its Q3 Earnings Call
- 13 days ago / globenewswire.comGenmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
- 14 days ago / cnbc.comA little-known biotech's high-stakes cancer bet just paid off and its shares doubled
- 19 days ago / seekingalpha.comGenmab A/S (GMAB) Discusses Phase III Cancer Data and Potential New Treatment Standards Transcript
- 19 days ago / marketbeat.comGenmab's Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches
- 20 days ago / benzinga.comGenmab Stock Hits 52-Week High - Here's Why
Add to Watchlist
Select watchlists to add or remove GMAB